Evidence map›Paper›PMID 34051857›Full record

ArticleStem cell research & therapy2021

Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation.

Sung-Tai Wei, Yen-Chih Huang, Jung-Ying Chiang, Chia-Ching Lin, Yu-Jung Lin, Woei-Cherng Shyu, Hui-Chen Chen, Chia-Hung Hsieh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  7. Article
  8. Article
  9. Engineering of Immune Microenvironment for Enhanced Tissue Remodeling.Tissue engineering and regenerative medicine · 2022
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sung-Tai Wei *Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Yen-Chih Huang *Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Jung-Ying ChiangGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Chia-Ching LinGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Yu-Jung LinGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Woei-Cherng ShyuGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Hui-Chen ChenGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Chia-Hung HsiehGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. chhsiehcmu@mail.cmu.edu.tw.ORCID 0000-0003-3463-1583
China Medical University · TWAsia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe major barriers to mesenchymal stem cell (MSC) therapy in rheumatoid arthritis (RA) are a low extent of tissue regeneration and insufficient immunomodulation after cell transplantation. In addition, the role of C-X-C chemokine receptor type 7 (CXCR7) and its mechanism of action in MSC-mediated osteogenic or chondrogenic differentiation and immunomodulation are unclear.

methodsGain of CXCR7 function on human MSCs was carried out by lentiviral vector-mediated CXCR7 overexpression or CXCR7 agonist, TC14012. These cells were determined the role and potential mechanisms for CXCR7-regulated MSC differentiation and immunomodulation using cellular and molecular assays. The therapeutic benefits in RA were investigated in rats with collagen-induced arthritis (CIA).

resultsCXCR7 was upregulated in MSCs during the induction of osteogenic or chondrogenic differentiation. Blockage of CXCR7 function inhibited osteogenic or chondrogenic differentiation of MSCs whereas gain of CXCR7 function had the opposite effects. Besides, MSCs with CXCR7 gain-of-function facilitated macrophage apoptosis and regulatory T cell differentiation in a co-culture system. Gain of CXCR7 function also promoted the production of anti-inflammatory soluble factors. A gene expression profiling assay and signaling reporter assays revealed that CXCR7 could regulate several candidate genes related to the PPAR, WNT, Hedgehog or Notch pathways, and their signaling activities, which are known to control cell differentiation and immunomodulation. Finally, MSCs with CXCR7 gain-of-function significantly reduced the articular index scores, ankle circumference, radiographic scores, histologic scores, and inflammation in rats with CIA compared with control MSCs.

conclusionsCXCR7 promotes the osteogenic and chondrogenic differentiation of MSCs and MSC-mediated immunomodulation by regulating several signaling pathways and anti-inflammatory soluble factors. MSCs with CXCR7 gain-of-function significantly ameliorate arthritic symptoms in a CIA model.

Indexed as

Arthritis, ExperimentalMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsCell DifferentiationImmunomodulationRatsReceptors, CXCRAckr3 protein, ratReceptors, CXCRCXC chemokine receptor 7differentiationimmunomodulationMesenchymal stem cellsrheumatoid arthritis

Identifiers

PMID34051857
PMCPMC8164772
OpenAlexW3164816373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.